249 related articles for article (PubMed ID: 20077523)
1. Risk management of nanomaterials.
Gwinn MR; Tran L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(2):130-7. PubMed ID: 20077523
[TBL] [Abstract][Full Text] [Related]
2. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
[TBL] [Abstract][Full Text] [Related]
3. Moving toward exposure and risk evaluation of nanomaterials: challenges and future directions.
Thomas T; Bahadori T; Savage N; Thomas K
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(4):426-33. PubMed ID: 20049808
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology: the next big thing, or much ado about nothing?
Maynard AD
Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243
[TBL] [Abstract][Full Text] [Related]
5. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
Oberdörster G
J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
[TBL] [Abstract][Full Text] [Related]
6. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
Hirose A; Nishimura T; Kanno J
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
[TBL] [Abstract][Full Text] [Related]
7. Exposure assessment approaches for engineered nanomaterials.
Abbott LC; Maynard AD
Risk Anal; 2010 Nov; 30(11):1634-44. PubMed ID: 20626687
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment and risk management of nanomaterials in the workplace: translating research to practice.
Kuempel ED; Geraci CL; Schulte PA
Ann Occup Hyg; 2012 Jul; 56(5):491-505. PubMed ID: 22752094
[TBL] [Abstract][Full Text] [Related]
9. Medical surveillance, exposure registries, and epidemiologic research for workers exposed to nanomaterials.
Trout DB; Schulte PA
Toxicology; 2010 Mar; 269(2-3):128-35. PubMed ID: 20006668
[TBL] [Abstract][Full Text] [Related]
10. [Health risks of engineered nanomaterials and nanotechnologies].
Savolainen K; Vainio H
Duodecim; 2011; 127(11):1097-104. PubMed ID: 21755801
[TBL] [Abstract][Full Text] [Related]
11. Nanomaterial health effects--part 1: background and current knowledge.
Powell MC; Kanarek MS
WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
[TBL] [Abstract][Full Text] [Related]
12. Sensors as tools for quantitation, nanotoxicity and nanomonitoring assessment of engineered nanomaterials.
Sadik OA; Zhou AL; Kikandi S; Du N; Wang Q; Varner K
J Environ Monit; 2009 Oct; 11(10):1782-800. PubMed ID: 19809701
[TBL] [Abstract][Full Text] [Related]
13. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
[TBL] [Abstract][Full Text] [Related]
14. Priority setting for risk assessment--the benefit of human experience.
Alonzo C; Laborde A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):692-6. PubMed ID: 16153990
[TBL] [Abstract][Full Text] [Related]
15. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry.
Fairbrother A; Fairbrother JR
Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165
[TBL] [Abstract][Full Text] [Related]
16. [Health effects of engineered nanomaterials].
Pietroiusti A; Magrini A; Bergamaschi A; Iavicoli I
G Ital Med Lav Ergon; 2010; 32(4 Suppl):287-9. PubMed ID: 21438282
[TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
18. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
19. Research strategies for safety evaluation of nanomaterials, Part I: evaluating the human health implications of exposure to nanoscale materials.
Thomas K; Sayre P
Toxicol Sci; 2005 Oct; 87(2):316-21. PubMed ID: 16049265
[TBL] [Abstract][Full Text] [Related]
20. Conscious worst case definition for risk assessment, part I: a knowledge mapping approach for defining most critical risk factors in integrative risk management of chemicals and nanomaterials.
Sørensen PB; Thomsen M; Assmuth T; Grieger KD; Baun A
Sci Total Environ; 2010 Aug; 408(18):3852-9. PubMed ID: 19945144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
